Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 2/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.56 |
| ▸ | PPIA | P62937 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492629 | 0.91 | CXCR2 (0.62) | CXCR1CXCR2PPIASGMS2BRD4 | |
| SCHEMBL7551257 | 0.89 | SGMS2 (0.53) | CXCR1CXCR2PPIAKMT2AMEN1 | |
| SCHEMBL7515957 | 0.88 | CXCR2 (0.58) | CXCR1CXCR2PPIAKMT2AMEN1 | |
| SCHEMBL7552006 | 0.86 | CXCR2 (0.57) | CXCR1CXCR2PPIAKMT2ALMNA | |
| SCHEMBL7488374 | 0.84 | SGMS2 (0.49) | CXCR1CXCR2PPIAKMT2AMEN1 | |
| SCHEMBL7489143 | 0.80 | PPIA (0.62) | CXCR1CXCR2PPIAKMT2AMEN1 | |
| SCHEMBL3707120 | 0.79 | CXCR1 (0.67) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL7514963 | 0.73 | CXCR2 (0.73) | CXCR1CXCR2KMT2AMEN1LMNA | |
| Urea SCHEMBL7511030 | 0.73 | PPIA (0.39) | PPIASGMS2LRRK2 | |
| SCHEMBL3705632 | 0.72 | CXCR2 (1.00) | CXCR1CXCR2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107949-A4 | PROCESS FOR PREPARING CERTAIN PHENYL UREA COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-6372933-B1 | REACTING BENZOXAZOLINONE WITH NUCLEOPHILIC ANILINE DERIVATIVE IN PRESENCE OF LEWIS ACID TO OPEN OXAZOLINONE RING TO FORM PHENYL UREA COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-1107949-A2 | PROCESS FOR PREPARING CERTAIN PHENYL UREA COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012472-A2 | PROCESS FOR PREPARING CERTAIN PHENYL UREA COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-09 | — | — | WO | claimed |
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6372933-B1 | REACTING BENZOXAZOLINONE WITH NUCLEOPHILIC ANILINE DERIVATIVE IN PRESENCE OF LEWIS ACID TO OPEN OXAZOLINONE RING TO FORM PHENYL UREA COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1107948-A4 | AN IMPROVED SYNTHESIS OF 3-HYDROXY-4-AMINO-BENZONITRILE | SMITHKLINE BEECHAM (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1107948-A1 | AN IMPROVED SYNTHESIS OF 3-HYDROXY-4-AMINO-BENZONITRILE | Smithkline Beecham (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| WO-2000012468-A1 | AN IMPROVED SYNTHESIS OF 3-HYDROXY-4-AMINO-BENZONITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR1 21/4885CXCR2 15/4885PPIA 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.